期刊
ALLERGY AND ASTHMA PROCEEDINGS
卷 31, 期 4, 页码 269-279出版社
OCEAN SIDE PUBLICATIONS INC
DOI: 10.2500/aap.2010.31.3364
关键词
Asthma deteriorations; clinical trial; combination therapy; formoterol; lung function; medium dose; mometasone furoate; quality of life; symptoms; uncontrolled asthma
类别
资金
- Merck Co
- Abbott
- Alcon
- AstraZeneca
- Ception
- Dey
- Dyax
- Genentech
- GSK
- MAP
- Med-Immune
- Novartis
- Sanofi-aventis
- Schering-Plough
- Sepracor
- TEVA
Asthma is a heterogeneous condition characterized by reduced lung function, chronic inflammation, and periodic asthma deteriorations. This study was performed to evaluate the effect of mometasone furoate (MF)/formoterol (F) combination, 200/10 mu g, administered twice daily (b.i.d.) on asthma deteriorations and pulmonary function in patients with asthma uncontrolled on medium-dose inhaled corticosteroid (ICS). After 2- to 3-week open-label run-in with MF 200 mu g b.i.d., patients (>= 12 years) were randomized to 26 weeks of treatment with MF/F 200/10 mu g, MF 200 mu kg, F 10 mu g, or placebo b.i.d. Coprimary end points were time to first asthma deterioration (MF/F versus F) and bronchodilation, assessed by the area under the curve of the change in forced expiratory volume in 1 second 0-12 hours (FEV(1) AUC(0-12h); MF/F versus MF). A total of 781 patients were randomized. Treatment with MF/F 200/10 mu g reduced asthma deteriorations and clinically judged deteriorations (i.e., deterioration resulting in emergency treatment, hospitalization, or treatment with additional excluded asthma medication systemic corticosteroids]). The proportion of patients experiencing asthma deteriorations was MF/F, 30.4%; MF, 33.9%; F, 54.0%; placebo, 55.6% (p < 0.001, MF/F versus F and placebo). There was a sixfold reduction in clinically judged deteriorations with MF/F versus F and placebo (p < 0.001). Lung function improved more rapidly with MF/F than MF and placebo. Mean change from baseline FEV(1) AUC(0-12h), at week 12 was MF/F, 11.7% versus MF, 5.7%; F, 8.5%; and placebo, 3.9% (p < 0.001). Treatment-related AEs were rare and similar across groups. Treatment with MF/F 200/10 mu g was effective in reducing the risk of asthma deteriorations. MF/F was safe and provided rapid and sustained bronchodilation in patients with asthma. (Allergy Asthma Proc 31:269-279, 2010; doi:10.2500/aap.2010.31.3364)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据